Rapport

Dassault Aviation: Availability of a complete form of the 2023 Annual Financial Report

Retrieved on: 
Thursday, March 14, 2024
Annual report, Dassault Aviation, Rapport, Aviation, Publication

Dassault Aviation complete version of the 2023 Annual Financial Report (Rapport financier annuel) as of 31 December 2023 is available to the public and has been filed with the French Financial Markets Authority (Autorité des Marchés Financiers), including in ESEF format.

Key Points: 
  • Dassault Aviation complete version of the 2023 Annual Financial Report (Rapport financier annuel) as of 31 December 2023 is available to the public and has been filed with the French Financial Markets Authority (Autorité des Marchés Financiers), including in ESEF format.
  • This financial annual report can be found on the company’s website at www.dassault-aviation.com, in the “Finance / Regulated information / 2024 Regulated information” and “Finance / Publications / 2024 Publications” sections.

Creators Union with DJ Jazzy Jeff: Love Of Da Game Edition Officially Opens Membership to Pioneer the Future of Creativity, Music and AI on the Blockchain

Retrieved on: 
Thursday, March 14, 2024
Software, Entertainment, Internet, Professional Services, Blockchain, Technology, Digital Cash Management, Digital Assets, Artificial Intelligence, General Entertainment, Celebrity, NFT, Music, XRP, Sony Music, SXSW, Rapport, DA, Digital twin, Turbocharger, Creativity, Ecosystem, DJ Jazzy Jeff, Movement

Creators Union with DJ Jazzy Jeff: Love Of Da Game Edition , the groundbreaking platform founded by legendary DJ Jazzy Jeff and technologist and Creator Mode Studios founder James Andrews, officially opens membership today after launching Tuesday at SXSW.

Key Points: 
  • Creators Union with DJ Jazzy Jeff: Love Of Da Game Edition , the groundbreaking platform founded by legendary DJ Jazzy Jeff and technologist and Creator Mode Studios founder James Andrews, officially opens membership today after launching Tuesday at SXSW.
  • The Creators Union token serves as the cornerstone of a decentralized ecosystem designed to foster collaboration, transparency and equitable opportunities within the creative economy.
  • “Artists deserve more than just payouts - they deserve deeper engagement, creative fulfillment and the chance to turn their vision into cultural movements.
  • That's the real power behind the Creators Union tokens,” said DJ Jazzy Jeff.

Digital Locations CEO Rich Berliner Discussed Future of 6G Wireless Technology with Top Industry Experts

Retrieved on: 
Wednesday, February 14, 2024
Electronic engineering, Wireless network, Mathematical sciences, Doctor of Philosophy, Mobile, Wireless, Google Scholar, Florida International University, WNCG, Radiology, University School, RFIC, National academy, Telecommunications, Virginia Tech, Radio, Theodore Rappaport, NYU, University, Field-programmable gate array, Associate, Electrical engineering, Medicine, Electricity, Fellow, Rapport

SANTA BARBARA, CA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Digital Locations, Inc. (OTCMKTS:DLOC), the developer of SatennaTM, a breakthrough technology that will enable delivery of high-speed Internet from satellites directly to smartphones all over the world, today announced that in a recent podcast, its CEO, Rich Berliner, spoke with Dr. Ted Rappaport, founding director of NYU Wireless, and Dr. Arjuna Madanayake, Associate Professor at Florida International University, about their work on channel modeling, precision timing, chip design, chip measurement and the future of 6G wireless.

Key Points: 
  • Ted Rapport and Arjuna Madanayake report on channel modeling, precision timing, chip design, chip measurement, and the future of 6G wireless.
  • During the conversation, both Dr. Rappaport and Dr. Madanayake stressed the importance of the standardized measurement facility they are creating.
  • Future wireless is going to have multiple antennas, multiple threads, and multiple parallel paths.
  • Dr. Rappaport is the founding director of NYU WIRELESS, the world's first academic research center to combine engineering, computer science, and medicine.

BioSpace Names Most Promising New Biopharma Companies to Watch in 2024

Retrieved on: 
Wednesday, January 3, 2024
Rapport, Global health, Nextgen, Creativity, Class, Therapy, News

DES MOINES, Iowa, Jan. 3, 2024 /PRNewswire/ -- BioSpace , the leading life sciences news and careers site, has announced its 2024 selections for the industry's most promising up-and-coming companies.

Key Points: 
  • DES MOINES, Iowa, Jan. 3, 2024 /PRNewswire/ -- BioSpace , the leading life sciences news and careers site, has announced its 2024 selections for the industry's most promising up-and-coming companies.
  • The NextGen Class of 2024 list showcases 30 innovative organizations demonstrating exciting potential.
  • This is the 10th year BioSpace has highlighted the most anticipated new biopharma companies from across the U.S.
  • "It is a testament to biopharma's commitment to advancing global health, perseverance and creativity, and we are proud to showcase these companies."

Rapport Therapeutics Appoints Chief Financial Officer

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Science, IPO, Sale, AstraZeneca, Abivax, RAPS, Esperion Therapeutics, Eli Lilly, Esperies, Insys Therapeutics, Multimedia, DSM-IV codes, Ferris State University, Therapy, Patient, Pharmaceutical industry, Rapport

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231030359557/en/
    “We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company,” said Abraham Ceesay, Chief Executive Officer of Rapport.
  • Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings.
  • Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.

Apparatix Adds Out-of-Home Ad Data to DOmedia Buying Platform

Retrieved on: 
Thursday, November 2, 2023
Kinetic, Rapport, Billups, OOH, Sales, Online shopping, COLUMBUS

COLUMBUS, Ohio, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Out-of-home (OOH) media operators can now use inventory data stored in Apparatix software to service advertisers through DOmedia, where global brands and local advertisers contract over $1B of OOH ads each year. The integration will help Apparatix users increase sales to local and national advertisers.

Key Points: 
  • COLUMBUS, Ohio, Nov. 2, 2023 /PRNewswire-PRWeb/ -- Out-of-home (OOH) media operators can now use inventory data stored in Apparatix software to service advertisers through DOmedia, where global brands and local advertisers contract over $1B of OOH ads each year.
  • "Increasing operational efficiency so agencies and advertisers can focus on higher value work has always been our goal," said Nick Sadler, CEO of DOmedia.
  • DOmedia began offering real-time OOH media availability data to agencies and advertisers in March 2021.
  • Apparatix users, which include many independent OOH media operators, will now be among the fastest and most effective at servicing buyers through DOmedia.

Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member

Retrieved on: 
Thursday, September 7, 2023
Mental Health, Health, Neurology, Research, Science, Pharmaceutical, Biotechnology, Molecule, Medicinal chemistry, Memorial Sloan Kettering Cancer Center, Senior, Samuel, Marketing, Ironwood Pharmaceuticals, Genomics, Journal of Medicinal Chemistry, Coronavirus Scientific Advisory Board, Multimedia, GV (company), Multiple sclerosis, Scio Diamond Technology Corporation, Genentech, Princeton University, BTK, Constipation, Genzyme, Chemistry, DSM-IV codes, Celera Corporation, Journal, Patient, Laboratory, Seizure, RAPS, American Cancer Society, Therapy, Pharmaceutical industry, Rapport, Boston College

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.
  • Ms. Gault comes to Rapport from Cyclerion Therapeutics, where she was Chief Operating Officer overseeing corporate and business development, portfolio strategy, new product planning and corporate strategy functions.
  • Ms. Gault also served at Genzyme Corporation in a variety of sales and marketing roles in the biosurgery division.
  • She currently serves on the boards of directors and scientific advisory boards of several biotech companies and is an advisor at Google Ventures.

Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Goldman Sachs, DSM-IV codes, ARCH Venture Partners, Science, Pain, Third Rock Ventures, Investment, Patient, Nervous system, Seizure, Nobel, Epilepsy, RAPS, Growth, Therapy, Pharmaceutical industry, Rapport, Citadel

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced that it has raised $150 million in Series B funding.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced that it has raised $150 million in Series B funding.
  • Concurrent with the round, Rapport has appointed Raymond Kelleher, M.D., Ph.D., Managing Director of Cormorant Asset Management, and James Healy, M.D., Ph.D., Managing Partner of Sofinnova Investments, to its Board of Directors.
  • “Rapport is pursuing a unique approach that exploits novel molecular insights with the goal of targeting ion channel receptors with unprecedented precision.
  • “I am eager to support Rapport as an investor and board member as the team continues to progress its programs in the clinic and extend what is possible in precision neuromedicine.”

Rapport Therapeutics Names Scientific Advisory Board

Retrieved on: 
Thursday, June 29, 2023
Health, Neurology, Other Science, Clinical Trials, Research, Science, Biotechnology, Molecular biology, Baylor University, Temperature, Howard Hughes Medical Institute, Genetics, Journal, National Academy of Medicine, Patient, Nervous system, Catalysis, RAPS, Eurosport 1, Royal Society, SAB, Nobel Prize, National academy, University, Emeritus, American Epilepsy Society, Janelia Research Campus, Royal, Princess of Asturias Awards, System, Scientific method, Safety, HHMI, Third Rock Ventures, FRS, Shaw Prize, Therapy, Epilepsy, Central nervous system, McMillan, RAP, NAS, Baylor College of Medicine, Nobel Prize in Chemistry, University of California, San Francisco, DSM-IV codes, American Academy, Buckingham Palace, Princeton University, Harvard Medical School, Nobel, United Kingdom, Nerve injury, Gene, Pharmaceutical industry, Chemistry, Rapport, Neuroscience, Pain, Physiology, Nature, Anatomy, Medicine

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.
  • Its members are David Julius, Ph.D., David MacMillan, Ph.D., David Clapham, M.D., Ph.D., Allan Basbaum, Ph.D., FRS and Jeffrey Noebels, M.D., Ph.D.
  • “Rapport has assembled what may well be the most impressive scientific advisory board in biotech, which includes some of the world’s most accomplished scientists,” said Steve Paul, M.D., Chairman of the Rapport Board of Directors, Co-Founder and Advisory Partner at Third Rock Ventures.
  • Dr. Clapham was HHMI’s vice president and chief scientific officer from 2016 to 2022.

Former IPG Executive Joins DOmedia to Accelerate Growth

Retrieved on: 
Thursday, May 18, 2023
RFP, Rapport, Advertising, OOH, IPG, Video game, Cryptocurrency, Sales

NEW YORK, May 18, 2023 /PRNewswire-PRWeb/ -- DOmedia, the most-used out-of-home (OOH) ad buying software in the U.S., announced today that Mike Cooper has joined the leadership team to focus on international expansion and will assist with their next-generation OOH planning products. Previously, Mike served as Global President of Rapport Worldwide, an Interpublic Group Company (IPG).

Key Points: 
  • Previously, Mike served as Global President of Rapport Worldwide, an Interpublic Group Company (IPG).
  • In 2023, over 25% of all agency-driven U.S. OOH ad dollars will be managed through DOmedia, including 6% of all programmatic OOH advertising.
  • 75% of BillboardsIn.com users have never purchased billboards or other OOH media before, and most agencies using DOmedia plan and buy exclusively within the platform.
  • Media operators interested in receiving RFPs and contracts through DOmedia can sign up on DOmedia.com